Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Radiation
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 2
2 studies reported at therapy level; 2 evidence entries itemised.
MouseRadiationBALB/cFemaleIntravenous (tail vein)32 ug per mouse (1.6 mg/kg body weight) in vivo; 10 ug/ml i…First dose 24 h after irradiation
Model: Total body irradiation with 7.25 Gy from a caesium gamma irradiator at 4.18 Gy/min; in vitro work used lineage-negative bone marrow cells and primary fibroblasts irradiated at 3 to 5 Gy
Thioredoxin given 24 h after 7.25 Gy total body irradiation raised 30-day survival to 70% versus 25% in saline-treated mice (p = 0.0273). Treated mice showed higher white blood cell and platelet counts, more KSL and SLAM+KSL cells, more CFU-GM and CFU-GEMM colonies and greater bone marrow cellulari…
Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.
MouseRadiationC57BL/6 wild-type and thioredoxin-transgenicFemaleIntraperitoneal
Model: Ultraviolet-B irradiation of skin causing acute inflammation and keratinocyte apoptosis
Ear swelling after UV-B was significantly reduced in TRX-transgenic mice compared with wild type. Intraperitoneal recombinant human thioredoxin reduced acute skin erythema and swelling, reduced neutrophil and lymphocyte infiltration and vessel calibre, significantly reduced sunburn cells, activated…
Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.
